OR WAIT null SECS
Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.
January 02, 2016
The bio/pharmaceutical industry will face increased scrutiny of product quality and cost drivers.
December 28, 2015
The FDA program that encourages biopharma companies to develop new treatments for rare and neglected diseases has been in the spotlight recently.
December 17, 2015
Janet Woodcock, director of the Center for Drug Evaluation, highlights FDA's priority list for 2016.
December 14, 2015
The use of drug compounding facilities to produce over-priced generic drugs raises quality and regulatory questions.
December 02, 2015
FDA confirmed quality focus while Congress moved to bolster biomedical innovation.
November 18, 2015
Robert Califf addresses questions about drug pricing at the Senate hearing to weigh his appointment to be the next commissioner of FDA.